Wedbush Weighs in on Compass Therapeutics, Inc.’s FY2022 Earnings (NASDAQ:CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPXGet Rating) – Research analysts at Wedbush lifted their FY2022 EPS estimates for Compass Therapeutics in a research report issued to clients and investors on Tuesday, August 2nd. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($0.36) for the year, up from their previous estimate of ($0.37). The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Compass Therapeutics’ Q4 2022 earnings at ($0.10) EPS, FY2023 earnings at ($0.47) EPS, FY2024 earnings at ($0.53) EPS, FY2025 earnings at ($0.57) EPS and FY2026 earnings at $0.64 EPS.

Several other equities research analysts also recently issued reports on CMPX. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Compass Therapeutics in a research report on Monday, May 23rd. B. Riley reissued a “buy” rating on shares of Compass Therapeutics in a research report on Wednesday, June 22nd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Compass Therapeutics presently has an average rating of “Buy” and a consensus price target of $10.00.

Compass Therapeutics Stock Up 3.9 %

Shares of CMPX stock opened at $2.66 on Thursday. The firm has a fifty day moving average of $2.69 and a 200-day moving average of $2.16. Compass Therapeutics has a 12-month low of $1.25 and a 12-month high of $4.75. The company has a market capitalization of $269.42 million and a price-to-earnings ratio of -6.40.

Compass Therapeutics (NASDAQ:CMPXGet Rating) last issued its quarterly earnings data on Monday, August 1st. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08).

Institutional Trading of Compass Therapeutics

Hedge funds have recently modified their holdings of the stock. Difesa Capital Management LP acquired a new stake in shares of Compass Therapeutics during the 4th quarter worth about $33,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Compass Therapeutics during the 2nd quarter worth about $37,000. Mirabella Financial Services LLP acquired a new stake in shares of Compass Therapeutics during the 4th quarter worth about $60,000. New Capital Management LP acquired a new stake in shares of Compass Therapeutics during the 2nd quarter worth about $69,000. Finally, Qube Research & Technologies Ltd lifted its stake in shares of Compass Therapeutics by 81.9% during the 1st quarter. Qube Research & Technologies Ltd now owns 52,842 shares of the company’s stock worth $72,000 after buying an additional 23,789 shares during the last quarter. Institutional investors and hedge funds own 66.04% of the company’s stock.

Insider Activity at Compass Therapeutics

In other news, CEO Thomas J. Schuetz acquired 20,000 shares of the firm’s stock in a transaction dated Thursday, May 26th. The stock was bought at an average price of $3.04 per share, with a total value of $60,800.00. Following the transaction, the chief executive officer now directly owns 5,211,873 shares in the company, valued at approximately $15,844,093.92. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Orbimed Advisors Llc acquired 90,712 shares of the firm’s stock in a transaction dated Monday, May 9th. The stock was bought at an average price of $1.56 per share, with a total value of $141,510.72. Following the transaction, the director now directly owns 14,601,031 shares in the company, valued at approximately $22,777,608.36. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Thomas J. Schuetz acquired 20,000 shares of the firm’s stock in a transaction dated Thursday, May 26th. The stock was purchased at an average cost of $3.04 per share, with a total value of $60,800.00. Following the transaction, the chief executive officer now owns 5,211,873 shares in the company, valued at $15,844,093.92. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 387,325 shares of company stock valued at $850,352. Corporate insiders own 29.80% of the company’s stock.

About Compass Therapeutics

(Get Rating)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that is in Phase I clinical trial for patients with solid tumors, such as small cell lung cancer and melanoma; and CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 for oncology area.

Further Reading

Earnings History and Estimates for Compass Therapeutics (NASDAQ:CMPX)

Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.